Refisolone
Refisolone ( , ; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and…
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Refisolone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD).[1][2][4][3] It is taken intranasally as a nasal spray.[1][2][3] The pharmacology of refisolone has been studied and reported.[5][6] The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023.[1][2][4][3] As of December 2025, refisolone is in phase 2 clinical trials for all indications.[1][4] However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.[3][7]
See also
edit edit source- List of neurosteroids § Pheromones and pherines
- List of investigational sex-hormonal agents
- List of investigational PMS/PMDD drugs
- List of investigational headache and migraine drugs
- Fasedienol (PH94B; Aloradine)
- Itruvone (PH10)
References
edit edit source- ^ a b c d e "VistaGen Therapeutics". AdisInsight. Springer Nature Switzerland AG. 2 December 2025. Retrieved 9 March 2026. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ a b c d "Pherin Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. 28 July 2024. Retrieved 9 March 2026. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ a b c d e "PH-80 Drug Profile". Ozmosi. Retrieved 9 March 2026. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ a b c "Delving into the Latest Updates on Refisolone". Synapse. PatSnap. 28 February 2026. Retrieved 9 March 2026. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on In Vitro Receptor Binding, Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans. The Menopause Society 2025 Annual Meeting. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Novel, Investigational, Rapid-Onset Non-Hormonal Treatment for Vasomotor Symptoms Due to Menopause. The Menopause Society 2025 Annual Meeting. Wikipedia revision 1342905761, retrieved 2026-11-18
- ^ Clinical trial number NCT01217775 for "Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (PH80-PMD)" at ClinicalTrials.gov Wikipedia revision 1342905761, retrieved 2026-11-18
External links
edit edit source Human pheromones and vomeropherines- ETA
- Fasedienol (PH94B; Aloradine)
- Itruvone (PH10)
- PDD
- PH15
- PH30
- PH56
- PH78
- PH84
- Refisolone (PH80; Salubrin)
- See also: Steroid hormones
Text derived from https://en.wikipedia.org/w/index.php?oldid=1342905761 under CC BY-SA 4.0; modifications have been made.